Quest Diagnostics

Intelligent Bio Solutions Unveils Key Performance Indicator Growth in the United Kingdom as Drug Screening Industry Combats Drug Test Cheating and Searches for Simpler, Faster, Non-Invasive and More Cost-Effective Solutions

Retrieved on: 
木曜日, 5月 23, 2024
WSJ, Quest, Risk, Workforce, The Wall Street Journal, FDA, Safety, Growth, Quest Diagnostics, Workplace, Pharmaceutical industry

These indicators have contributed to the Company’s growth as the drug screening industry continues to combat drug test cheating and searches for simpler, faster, non-invasive, and more cost-effective solutions.

Key Points: 
  • These indicators have contributed to the Company’s growth as the drug screening industry continues to combat drug test cheating and searches for simpler, faster, non-invasive, and more cost-effective solutions.
  • As of March 31, 2024, INBS provided its innovative, rapid, non-invasive drug testing solutions to more than 400 customers across more than 15 industries in the UK.
  • The Company’s increasing market share in the UK suggests a growing need for effective testing solutions that address global drug challenges, including drug test cheating.
  • “Our drug testing solution addresses several key industry concerns, including simplifying the process, rapid on-site results, non-invasive administration, and cost-effectiveness.

Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference

Retrieved on: 
火曜日, 5月 7, 2024
Quest Diagnostics, DGX, Conference, Q&A

SECAUCUS, N.J., May 7, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on Wednesday, May 29, 2024, at 10:20 a.m. Eastern Time.

Key Points: 
  • SECAUCUS, N.J., May 7, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on Wednesday, May 29, 2024, at 10:20 a.m. Eastern Time.
  • The fireside chat and Q&A session will be webcast live during the conference and will be available on the company's investor relations page which can be accessed at ir.QuestDiagnostics.com .
  • In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until June 28, 2024.

MICHAEL J. ASSELTA JOINS COMPASSUS AS CEO

Retrieved on: 
火曜日, 5月 7, 2024
Health, Partnership, Growth, Quest Diagnostics, Management

BRENTWOOD, Tenn., May 7, 2024 /PRNewswire/ -- Compassus, a leading national provider of integrated home-based care services, announced today that its board of directors has appointed Michael J. Asselta as CEO. He succeeds David Grams, who will serve in an interim advisory role to help ensure a seamless transition.

Key Points: 
  • BRENTWOOD, Tenn., May 7, 2024 /PRNewswire/ -- Compassus , a leading national provider of integrated home-based care services, announced today that its board of directors has appointed Michael J. Asselta as CEO.
  • Compassus board of directors has appointed Michael J. Asselta as CEO.
  • "Compassus continues to build national momentum in executing its shared mission with long-standing provider and payor partners to expand access to best-in-class home-based care services.
  • "Compassus has a strong reputation for excellence and high-quality, home-based care across the country, which continues to be realized through its integrated care model and growth in market-leading partnerships," said Asselta.

Quest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital Officer

Retrieved on: 
月曜日, 5月 6, 2024
Chase Bank, University, JPMorgan Chase, Informatics, General Electric, Oak Street, Health, CVS Health, Quest Diagnostics, Information technology, Digital, Engineering, Senior, Fiserv, MBA, Oak Street Health, DGX, Moses Austin, Management

SECAUCUS, N.J., May 6, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technology healthcare business leader, has been named Senior Vice President and Chief Information and Digital Officer (CIDO).

Key Points: 
  • SECAUCUS, N.J., May 6, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technology healthcare business leader, has been named Senior Vice President and Chief Information and Digital Officer (CIDO).
  • Mr. Balakumar, based at the company's headquarters in Secaucus, N.J., is responsible for leading information technology, data informatics and digital solutions for Quest Diagnostics.
  • Prior to joining Quest, Murali was Chief Information Officer at Oak Street Health, which was acquired by CVS Health in 2023.
  • Prior to Oak Street, Murali was Chief Information Officer for Card Services at Fiserv and has also held IT leadership roles at JPMorgan Chase Bank and General Electric.

Weekly Recap: 13 Press Releases You Might Have Missed

Retrieved on: 
金曜日, 5月 3, 2024
Giant, Harvard University, Southwest Airlines, International Space Station, Commercial Crew Program, NASA, TIME, Food, Boeing Starliner, PR Newswire, Acceleration, Sunita Williams, News, Male, Celebrity Cruises, Inauguration, Information technology, Weakness, Life, Marie Cassidy, Database, Hard Rock Cafe, Immigration, Stagwell, Geography, Starliner, Health, Eli Lilly, Transport, Royal Caribbean International, Female, Digital, ADP, Related, PayPal, WNBA, Trump, Boeing, StubHub, Meal, Quest Diagnostics, Indiana Fever, Telecommunications, Letter, Growth

NEW YORK, May 3, 2024 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.

Key Points: 
  • NEW YORK, May 3, 2024 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire.
  • To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.
  • Click on the press release headlines to access accompanying multimedia assets that are available for download.
  • These are just a few of the recent press releases that consumers and the media should know about.

Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI

Retrieved on: 
水曜日, 5月 1, 2024
Cytogenetics, Hospital, Prognosis, Research, International, American Cancer Society, MD, Digital, Pathology, Transport, Growth, Quest Diagnostics, Intelligence, Marie Cassidy, Diagnosis, Senior, Patient, Microbiology, Acquisition, Workforce, DGX, Medical imaging

SECAUCUS, N.J. and BOSTON, May 1, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.

Key Points: 
  • Under the terms of a definitive agreement, Quest will acquire select assets of PathAI Diagnostics, the business of PathAI that provides anatomic and digital pathology laboratory services.
  • At closing, PathAI Diagnostics' state-of-the-art digitized laboratory in Memphis, Tennessee will become Quest's AI and digital R&D and solutions center, supporting Quest's specialty pathology businesses, AmeriPath and Dermpath Diagnostics.
  • Under separate agreements, Quest will license PathAI's AISight™ digital pathology image management system to support its pathology laboratories and customer sites in the United States.
  • "The PathAI Diagnostics laboratory in Memphis will allow Quest to accelerate its digital journey with an already digitized laboratory."

Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease

Retrieved on: 
月曜日, 4月 22, 2024
Cerebrospinal fluid, Protein, Test management, Risk, Blood, Apolipoprotein E, Plasma, MD, PET, AB, Research, Dementia, Quest Diagnostics, Alzheimer's Association, Patient, Physician, CSF, Diagnosis, Biomarker, Risk assessment, DGX, Frontiers, Journal, Deficit spending, Medical imaging

SECAUCUS, N.J., April 22, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the launch of a new blood biomarker test for phosphorylated tau 217, or p-tau217. P-tau217 is a biomarker associated with Alzheimer's Disease (AD), supported by research as useful for an early diagnosis of AD.

Key Points: 
  • P-tau217 is a biomarker associated with Alzheimer's Disease (AD), supported by research as useful for an early diagnosis of AD.
  • With a physician's test order, patients may provide a blood draw for testing from any of Quest's 2,000 patient service centers in the United States.
  • "We know diagnosing AD is challenging, and believe our AD Detect™ services can help individuals better understand their possible risk."
  • A leader in neurology, Quest Diagnostics is committed to developing innovative laboratory services to aid in evaluating patient risk of Alzheimer's Disease and other dementias.

Crestron Innovation Transforms New York Giants Draft Room Upgrade into Fully Immersive Football and Business Operations Hub

Retrieved on: 
火曜日, 4月 16, 2024
Magnet, System, Social media, Innovation, Crestron Electronics, Communication, Partnership, New York Giants, Quest Diagnostics, Television, Rest, Senior, Data analysis, Football, Organization, Management

EAST RUTHERFORD, N.J., April 16, 2024 /PRNewswire/ -- The New York Giants and Crestron are proud to announce an innovative partnership that merges football performance with business operations driven by technology that places both organizations at the forefront of their fields. Crestron, a leader in technologies that remove barriers to connection, collaboration, communication, comfort, and control, sets the standard for intelligent business solutions that empower companies to achieve more.

Key Points: 
  • The Giants Draft Room was transformed from manual magnets to Crestron-controlled displays and is now a benchmark for state-of-the-art technology integrations.
  • Giants Director of Football Data & Innovation, Ty Siam, worked alongside Crestron to digitize and modernize the draft room.
  • "The draft room is the hub for many of these activities and Crestron met the demands of this impactful space.
  • Go behind the scenes and learn more about how the Giants have leveraged Crestron technology in the draft room and throughout the Quest Diagnostics Training Center.

AMD Lead Independent Director Nora Denzel and Best Buy Board Chair-Elect David Kenny to Co-Chair the 2024 NACD Blue Ribbon Commission on Board Oversight of Technology

Retrieved on: 
火曜日, 4月 16, 2024
NACD, City, Toyota, Vanguard, Tufts University, Pentair, Business, Intelligence, Harvard Business School, Chairperson, SIPA, The Weather Company, CSX Corporation, HPE, AMD, Trust, Asurion, Nashville Electric Service, Sally Beauty Holdings, General Atlantic, Blue-ribbon committee, CIO, Head, Weather Underground (weather service), RET, ServiceNow, United States Air Force, International, Consumer, General counsel, Blockchain, Advisory board, Research, Artificial intelligence, Commission, Drexel University, World Economic Forum, Booking Holdings, Former, UMB, Akamai Technologies, Organization, Weather, Public affairs, UMB Financial Corporation, Quest Diagnostics, Gen, Senior, Intuit, Innovation Hub, Growth, IBM, Management

WASHINGTON, April 16, 2024 /PRNewswire/ -- NACD today announced it has appointed a commission to examine board oversight of technology, prompted in part by the emergence of disruptive technologies like generative artificial intelligence which are impacting all business operations. The 2024 NACD Blue Ribbon Commission will be spearheaded by the following co-chairs:

Key Points: 
  • The 2024 NACD Blue Ribbon Commission will be spearheaded by the following co-chairs:
    Nora Denzel , NACD.DC™, Lead Independent Director, Advanced Micro Devices, Director, Gen Digital and NACD, and Former C-suite Technology Executive at Intuit, HPE and IBM.
  • David Kenny , Board Chair-Elect, Best Buy, Executive Chair, Nielsen and former CEO of Digitas, Akamai, Publicis, The Weather Company and Nielsen.
  • Directors cited the increasing pace of technological change as a top priority for 2024 in the most recent NACD Directors Outlook .
  • David Kenny , Board Chair-Elect, Best Buy; Executive Chair, Nielsen; and former CEO of Digitas, Akamai, Publicis, The Weather Company and Nielsen.

EarlyDiagnostics, Inc. Co-CEO Gregory C. Critchfield, M.D. M.S., Receives Utah Governor's Medal for Science and Technology

Retrieved on: 
月曜日, 4月 15, 2024
Science, Genetics, Myriad Genetics, Cancer, Medal, Patient, Organization, Knowledge, Quest Diagnostics, Management

LOS ANGELES, April 15, 2024 /PRNewswire/ -- EarlyDiagnostics ("EarlyDx"), the leading company in world-class liquid biopsy detection of early cancers and other conditions is pleased to announce today that Co-CEO Gregory C. Critchfield, M.D. M.S., has received the State of Utah's Governor's Medal for his numerous science and technology contributions in industry.

Key Points: 
  • M.S., has received the State of Utah's Governor's Medal for his numerous science and technology contributions in industry .
  • "It is an honor to receive the Governor's Medal for Science and Technology for the industry category.
  • "This honor is well-deserved for his visionary leadership and transformative impact at Quest Diagnostics, Myriad Genetics, and Sera Prognostics.
  • Dr. Critchfield's wealth of knowledge and experience will help propel EarlyDiagnostics to the forefront of early cancer detection and personalized medicine."